top of page

Search Results

Search this site

658 results found with an empty search

  • AstraZeneca invests $2bn in Summit Therapeutics and expands ivonescimab cancer collaboration

    AstraZeneca is investing $2bn in Summit Therapeutics alongside a clinical collaboration focused on combinations involving the PD-1/VEGF bispecific antibody ivonescimab. The companies plan to evaluate ivonescimab with AstraZeneca oncology medicines, beginning with the antibody-drug conjugate sonesitatug vedotin. The transaction combines a major equity investment with expanded clinical collaboration around one of the industry's closely watched PD-1/VEGF programmes. Field Content Alert Type Deals Companies AstraZeneca; Summit Therapeutics Deal Type Equity investment and clinical collaboration Asset or Company Ivonescimab Therapy Area(s) Oncology Technology or Modality PD-1/VEGF bispecific antibody Deal Value $2bn equity investment Development Stage Clinical development Geography Global collaboration What Happened AstraZeneca announced a $2bn equity investment in Summit Therapeutics alongside a clinical collaboration to evaluate combinations involving ivonescimab and AstraZeneca oncology medicines. Why It Matters The agreement expands AstraZeneca's exposure to the emerging PD-1/VEGF bispecific field while creating opportunities to evaluate ivonescimab alongside assets from its established oncology portfolio. Supporting Context The collaboration is expected to begin by evaluating ivonescimab in combination with AstraZeneca's antibody-drug conjugate sonesitatug vedotin. Strategic Rationale AstraZeneca gains strategic exposure to Summit and an opportunity to explore combinations between ivonescimab and its own oncology pipeline. Potential Impact The collaboration could generate new combination regimens involving PD-1/VEGF inhibition and AstraZeneca oncology therapies if clinical studies support their use. Key Takeaway AstraZeneca is making a $2bn strategic investment in Summit while expanding clinical work around ivonescimab combination therapies. What to Watch Initiation and results of combination studies involving ivonescimab and AstraZeneca oncology assets. Primary Source AstraZeneca Relevant Date 28 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • STADA and SBP Group partner on Keytruda biosimilar and up to three additional biosimilar programmes

    STADA and SBP Group have launched a strategic biosimilars partnership beginning with a proposed Keytruda biosimilar and providing a framework for up to three additional programmes. The initial programme covers TQB3570, a proposed pembrolizumab biosimilar, with CTTQ responsible for development, manufacturing and supply and STADA receiving exclusive commercial rights across multiple European and CIS markets. The agreement also gives the partners a framework for up to three additional oncology and immunology biosimilars, substantially broadening the potential scope of the collaboration. Field Content Article Type Deals Companies STADA; SBP Group; CTTQ Deal Type Strategic biosimilars partnership Initial Asset TQB3570 Reference Product Keytruda (pembrolizumab) Therapy Areas Oncology; immunology Technology/Modality Monoclonal antibody biosimilars Programme Scope TQB3570 plus framework for up to three additional biosimilar programmes Commercial Territories European Union; Switzerland; United Kingdom; CIS, with options covering additional territories What Happened STADA and SBP Group launched a strategic partnership initially covering TQB3570, a proposed pembrolizumab biosimilar, with a framework for up to three additional biosimilars. Why It Matters The partnership combines a major biosimilar opportunity around Keytruda with the potential creation of a broader oncology and immunology portfolio. Development Responsibilities CTTQ will develop, manufacture and supply the products while STADA receives exclusive commercial rights in agreed territories. Strategic Rationale The arrangement combines SBP Group and CTTQ's development and manufacturing capabilities with STADA's established European biosimilars commercial infrastructure. Potential Impact The collaboration could create multiple new biosimilar competitors across major oncology and immunology biologic markets. Key Takeaway STADA and SBP Group are building a multi-product biosimilars partnership starting with a proposed Keytruda biosimilar. What to Watch Development progress for TQB3570, regulatory filings and selection of the additional biosimilar programmes. Primary Source STADA Relevant Date 28 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • FDA approves Teva's DEGEVMA biosimilar to Xgeva across all reference-product indications

    The FDA has approved Teva's DEGEVMA as a biosimilar to Xgeva across all reference-product indications, expanding competition in denosumab treatment. DEGEVMA (denosumab-adet) is approved for indications including prevention of skeletal complications in adults with advanced cancer involving bone, giant cell tumour of bone and hypercalcaemia of malignancy. The approval marks Teva's second FDA-approved biosimilar of 2026 and adds another denosumab option to the US biologics market. Field Content Article Type Approvals Drug Name Denosumab-adet Brand Name DEGEVMA Company Teva Pharmaceuticals Reference Product Xgeva (denosumab) Regulatory Authority U.S. Food and Drug Administration Approval Type Biosimilar approval Indications All approved reference-product indications Therapy Areas Oncology; bone disease Technology/Modality Monoclonal antibody biosimilar Geography United States What Happened The FDA approved DEGEVMA as a biosimilar to Xgeva across all indications of the reference product. Why It Matters The approval expands biosimilar competition for denosumab and may increase treatment options for patients requiring Xgeva-class therapy. Supporting Context Indications include prevention of bone complications associated with advanced cancer, giant cell tumour of bone and hypercalcaemia of malignancy. Strategic Context DEGEVMA is Teva's second FDA-approved biosimilar of 2026. Potential Impact Additional biosimilar competition could broaden access to denosumab therapy in the United States. Key Takeaway DEGEVMA gives Teva an FDA-approved biosimilar to Xgeva across all reference-product indications. What to Watch US commercial launch, pricing, payer coverage and adoption relative to Xgeva and competing denosumab biosimilars. Primary Source Teva Pharmaceuticals Relevant Date 28 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • FDA approves Emcitate as first treatment for MCT8 deficiency

    The FDA has approved Emcitate as the first treatment for MCT8 deficiency, providing a therapy for the peripheral thyrotoxicosis associated with this ultra-rare genetic disorder. Emcitate (tiratricol) is approved for adults and paediatric patients with MCT8 deficiency, also known as Allan-Herndon-Dudley syndrome. The first-in-disease approval provides a treatment designed to act without relying on the defective MCT8 transporter responsible for the disorder. Field Content Article Type Approvals Drug Name Tiratricol Brand Name Emcitate Regulatory Authority U.S. Food and Drug Administration Approval Type First FDA-approved treatment for MCT8 deficiency Indication Peripheral thyrotoxicosis in adults and paediatric patients with MCT8 deficiency Therapy Areas Rare disease; endocrinology; neurology Disease MCT8 deficiency / Allan-Herndon-Dudley syndrome Technology/Modality Thyroid hormone analogue Geography United States What Happened The FDA approved Emcitate for peripheral thyrotoxicosis in adults and paediatric patients with MCT8 deficiency. Why It Matters Emcitate is the first FDA-approved treatment for MCT8 deficiency, addressing an ultra-rare genetic disorder with no previously approved therapy. Supporting Context MCT8 deficiency results from defects in the MCT8 thyroid hormone transporter and is also known as Allan-Herndon-Dudley syndrome. Potential Impact The approval establishes the first US pharmacological treatment option for patients with MCT8 deficiency. Key Takeaway Emcitate becomes the first FDA-approved treatment for MCT8 deficiency. What to Watch US launch, patient access and longer-term evidence from treatment in adults and children. Primary Source U.S. Food and Drug Administration Relevant Date 28 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Merck licenses SciBrunch KRAS G12D inhibitor in deal worth up to $2.13bn

    Merck has secured exclusive worldwide rights to SciBrunch Therapeutics' preclinical KRAS G12D inhibitor SPR2015 in an oncology licensing transaction worth up to $2.13 billion. SciBrunch will receive $400 million upfront, with additional development, commercial and other milestone payments potentially taking the total transaction value to $2.13 billion. The agreement gives Merck a preclinical oral KRAS G12D (ON) inhibitor targeting one of the most important oncogenic mutations across multiple tumour types. Field Content Article Type Deals Companies Merck; SciBrunch Therapeutics Deal Type Exclusive global licensing agreement Asset SPR2015 Therapy Areas Oncology Technology/Modality Oral KRAS G12D (ON) inhibitor Development Stage Preclinical Upfront Payment $400 million Potential Deal Value Up to $2.13 billion Geography Worldwide What Happened Merck secured exclusive worldwide rights to SciBrunch Therapeutics' investigational oral KRAS G12D (ON) inhibitor SPR2015. Why It Matters The transaction adds a targeted oncology programme directed at KRAS G12D, a major oncogenic driver across several difficult-to-treat cancers. Supporting Context SPR2015 is a preclinical small-molecule programme designed to inhibit the active ON state of KRAS G12D. Strategic Rationale Merck gains a potentially differentiated KRAS-targeted asset for its oncology pipeline while SciBrunch receives substantial upfront funding and downstream milestone opportunities. Potential Impact Successful development could expand targeted treatment options for patients with KRAS G12D-mutated cancers. Key Takeaway Merck is paying $400 million upfront for SPR2015 in a licensing transaction worth up to $2.13 billion. What to Watch IND-enabling development, entry into clinical trials and initial evidence of activity across KRAS G12D-mutated tumours. Primary Source Merck Relevant Date 28 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • EU Council formally adopts sweeping pharmaceutical legislation reform

    The Council has formally adopted its position on the EU pharmaceutical package, moving the bloc's largest overhaul of medicines legislation in decades toward its final legislative stages. The reform covers medicine authorisation, regulatory data and market protection, supply obligations, orphan-drug incentives, antimicrobial resistance and changes to the Bolar exemption. The regulation and directive still require adoption by the European Parliament before the new pharmaceutical framework can enter into force. Field Content Article Type Industry Updates Development EU pharmaceutical legislation reform Institution Council of the European Union Policy Area Pharmaceutical and medicines regulation Legislative Instruments EU pharmaceutical package regulation and directive Geography European Union What Happened The Council formally adopted its first-reading position on the regulation and directive forming the EU pharmaceutical package. Why It Matters The package represents the most extensive reform of EU pharmaceutical legislation in decades and will reshape important rules governing medicines development, authorisation, incentives and supply. Key Measures Changes cover regulatory and market-protection rules, medicine-supply obligations, orphan-drug incentives, the Bolar exemption and incentives addressing antimicrobial resistance. Legislative Status Council first-reading position formally adopted; European Parliament adoption remains required. Potential Impact Pharmaceutical and biotechnology companies operating in Europe will need to adapt regulatory, intellectual-property and market-access strategies to the revised framework. Key Takeaway The EU pharmaceutical reform has passed a major Council milestone and is moving toward completion of the legislative process. What to Watch European Parliament adoption, publication of the final legislation and implementation timelines for the new rules. Primary Source Council of the European Union Relevant Date 28 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • European Commission authorises Nezglyal for cerebral adrenoleukodystrophy

    The EU authorisation introduces a pharmacological treatment for eligible boys with cerebral adrenoleukodystrophy under exceptional circumstances. Nezglyal has received EU-wide marketing authorisation for boys aged 2 to 12 years with cerebral adrenoleukodystrophy who meet specified MRI and neurological criteria. The orphan medicine was authorised under exceptional circumstances and will be subject to additional monitoring as evidence continues to develop following approval. Field Content Alert Type Approvals Product Nezglyal Indication Cerebral adrenoleukodystrophy (cALD) Patient Population Boys aged 2 to 12 years meeting specified MRI and neurological criteria Regulator European Commission / European Medicines Agency Regulatory Status EU-wide marketing authorisation under exceptional circumstances Orphan Status Orphan medicine Monitoring Subject to additional monitoring What Happened Nezglyal received EU-wide marketing authorisation for eligible boys with cerebral adrenoleukodystrophy. Why It Matters The authorisation provides a pharmacological treatment option for a severe rare neurological manifestation of adrenoleukodystrophy. Regulatory Context The medicine was authorised under exceptional circumstances and is subject to additional monitoring. Potential Impact Eligible children with cALD gain a newly authorised treatment option across the European Union. Key Takeaway Nezglyal has secured EU authorisation for a defined paediatric cerebral adrenoleukodystrophy population. What to Watch European launch, country-level access decisions and collection of additional post-authorisation evidence. Primary Source European Medicines Agency Relevant Date 21 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • FDA expands Olumiant approval to adolescents with severe alopecia areata

    The expanded indication extends Lilly's JAK inhibitor to adolescents aged 12 years and older with severe alopecia areata. The FDA has expanded the approval of Olumiant (baricitinib) to include patients aged 12 years and older with severe alopecia areata. The decision was supported by the Phase III BRAVE-AA-PEDS study, extending a treatment previously available in the US for adults with severe alopecia areata to eligible adolescents. Field Content Alert Type Approvals Company Eli Lilly and Company Product Olumiant (baricitinib) Indication Severe alopecia areata Patient Population Patients aged 12 years and older Technology/Modality JAK inhibitor Regulator U.S. Food and Drug Administration Regulatory Status Expanded FDA approval Clinical Study Phase III BRAVE-AA-PEDS What Happened FDA expanded Olumiant's approval to include adolescents aged 12 years and older with severe alopecia areata. Why It Matters The decision extends an established systemic treatment for severe alopecia areata to a younger patient population. Supporting Evidence The approval was supported by the Phase III BRAVE-AA-PEDS study. Previous Population Olumiant was previously approved in the US for adults with severe alopecia areata. Potential Impact Eligible adolescents with severe alopecia areata gain access to an FDA-approved systemic treatment already used in adults. Key Takeaway Olumiant's US alopecia areata indication now covers patients from age 12. What to Watch Adolescent uptake, treatment guidelines and post-approval safety and effectiveness data. Primary Source Eli Lilly and Company Relevant Date 25 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • FDA approves Atebrioz for fibrodysplasia ossificans progressiva

    The FDA approval adds an oral ALK2 inhibitor for patients aged 12 years and older with the ultra-rare genetic disorder fibrodysplasia ossificans progressiva. Atebrioz (zilurgisertib) has been approved by the FDA to reduce the volume of new heterotopic ossification in adults and paediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva. The approval, supported by the pivotal PROGRESS study, makes Atebrioz the third FDA-approved treatment for FOP and adds an oral therapy targeting the ALK2 pathway. Field Content Alert Type Approvals Company Mirum Pharmaceuticals Product Atebrioz (zilurgisertib) Indication Fibrodysplasia ossificans progressiva (FOP) Patient Population Adults and paediatric patients aged 12 years and older Technology/Modality Oral ALK2 inhibitor Regulator U.S. Food and Drug Administration Regulatory Status FDA approved What Happened FDA approved Atebrioz to reduce the volume of new heterotopic ossification in patients with FOP aged 12 years and older. Why It Matters The approval adds a new oral treatment option for an ultra-rare genetic disorder characterised by progressive formation of bone in soft tissues. Supporting Evidence The approval was supported by the pivotal PROGRESS study. Competitive Context Atebrioz becomes the third FDA-approved treatment for FOP. Potential Impact The therapy expands treatment options for eligible adolescents and adults living with FOP. Key Takeaway Atebrioz provides a new FDA-approved oral ALK2-targeted treatment for FOP. What to Watch US launch, clinical uptake and longer-term evidence on control of heterotopic ossification. Primary Source U.S. Food and Drug Administration Relevant Date 25 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • FDA approves Juvmo for adults with Parkinson's disease

    The approval introduces a selective dopamine D1/D5 receptor partial agonist as a new oral treatment option for adults with Parkinson's disease. Juvmo (tavapadon) has been approved by the FDA for the treatment of Parkinson's disease in adults. The approval follows the Phase III TEMPO clinical programme and brings a selective dopamine D1/D5 receptor partial agonist into the US Parkinson's treatment landscape. Field Content Alert Type Approvals Product Juvmo (tavapadon) Indication Parkinson's disease Patient Population Adults Technology/Modality Oral selective dopamine D1/D5 receptor partial agonist Regulator U.S. Food and Drug Administration Regulatory Status FDA approved Clinical Programme Phase III TEMPO programme What Happened FDA approved Juvmo for the treatment of Parkinson's disease in adults. Why It Matters The approval introduces a new oral treatment using selective partial agonism of dopamine D1 and D5 receptors. Supporting Evidence The regulatory programme was supported by the Phase III TEMPO studies. Therapeutic Area Neurology Potential Impact Juvmo adds another pharmacological option for the management of Parkinson's disease in adults. Key Takeaway Juvmo brings a selective D1/D5 receptor partial agonist to the US Parkinson's disease market. What to Watch Commercial launch, prescribing uptake and positioning within existing Parkinson's treatment pathways. Primary Source U.S. Food and Drug Administration Relevant Date 25 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Atavistik Bio and Roche sign allosteric drug discovery collaboration worth up to $1.9bn

    The collaboration gives Roche access to Atavistik Bio's AMPS platform to discover allosteric small molecules across cardiovascular, renal and metabolic disease targets. Roche and Atavistik Bio have entered a multi-target research collaboration using Atavistik's AMPS platform to identify and develop allosteric small-molecule therapies. Atavistik will receive $70 million upfront and could earn up to $1.9 billion in milestone payments, as well as tiered royalties on resulting products. Field Content Alert Type Deals Companies Atavistik Bio; Roche Deal Type Multi-target research collaboration Technology/Platform AMPS allosteric drug discovery platform Therapy Areas Cardiovascular, renal and metabolic diseases Technology/Modality Allosteric small molecules Upfront Payment $70 million Potential Milestones Up to $1.9 billion Additional Economics Tiered royalties What Happened Roche entered a collaboration with Atavistik Bio to discover and develop allosteric small-molecule therapies against multiple targets. Why It Matters The agreement pairs Roche's drug-development capabilities with Atavistik's platform for identifying allosteric binding opportunities. Strategic Rationale The collaboration is designed to generate new medicines against cardiovascular, renal and metabolic disease targets. Potential Impact Successful programmes could broaden Roche's pipeline while validating Atavistik's AMPS platform across multiple targets. Key Takeaway The collaboration carries potential economics of nearly $2 billion in upfront and milestone payments before royalties. What to Watch Target progression, candidate nominations and movement of programmes into clinical development. Primary Source Atavistik Bio Relevant Date 24 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

  • Sun Pharma licenses global rights to LIB Therapeutics' cholesterol drug lerodalcibep

    The agreement gives Sun Pharma rights to the once-monthly PCSK9 inhibitor lerodalcibep across global markets excluding the US and China. Sun Pharma has secured exclusive licensing, commercialisation and manufacturing rights to LIB Therapeutics' lerodalcibep worldwide outside the US and China. The deal adds an EU-approved once-monthly PCSK9 inhibitor, marketed as Lyrokaul in Europe, to Sun Pharma's portfolio in exchange for undisclosed upfront and milestone payments plus royalties. Field Content Article Type Deals Companies Sun Pharma; LIB Therapeutics Asset Lerodalcibep Brand Lyrokaul in the European Union Therapy Area Cardiovascular disease / lipid management Target PCSK9 Technology/Modality Once-monthly injectable PCSK9 inhibitor Geography Worldwide excluding the US and China Deal Value Financial amounts not disclosed Deal Economics Upfront payment, milestone payments and royalties What Happened Sun Pharma secured exclusive rights to lerodalcibep in markets worldwide excluding the US and China. Why It Matters The transaction gives Sun Pharma access to a differentiated once-monthly cholesterol-lowering therapy with an existing European regulatory approval. Strategic Rationale The agreement expands Sun Pharma's cardiovascular portfolio and provides a platform for commercialising lerodalcibep across multiple international markets. Potential Impact The partnership could broaden global access to lerodalcibep while strengthening Sun Pharma's position in lipid management. Key Takeaway Sun Pharma gains broad international rights to LIB Therapeutics' once-monthly PCSK9 inhibitor. What to Watch Market launches, reimbursement decisions and commercial uptake outside the US and China. Primary Source Sun Pharma Relevant Date 28 September 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

bottom of page